Silence Therapeutics (SLN) Stock Price, Quote, News & History | Benzinga

SPY772.55+0.46%QQQ725.82+1.14%BTC/USD84,559.40+1.95%DIA525.59+0.23%GLD378.65+0.26%TLT80.23+0.12%

Silence Therapeutics PLC (SLN) Stock Price, Quote, News & History

SLNNASDAQ

Trade with Public

Trade with Public

$19.64

0.0350.18%

Last update: Oct 21, 12:01 PM

$19.62

0.010.05%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$19.61

Close

-

Volume / Avg.

1.28M / 2.30M

Day Range

$19.60 - $19.65

52 Wk Range

4.19 - 19.61

Market Cap

$1.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

80

Short Interest

5.02%

Days to Cover

3.07

Recent Silence Therapeutics PLC News

Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone

Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.

Avi Kapoor

Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.

Shivdeep Dhaliwal

Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39. The S&P 500 also

Avi Kapoor

Why Is Silence Therapeutics Stock Skyrocketing Monday?

Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.

Vandana Singh

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-42.26M

Investing Cash Flow (TTM)

72.89M

Financing Cash Flow (TTM)

2.00K

Free Cash Flow (TTM)

-42.27M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

30.63M

Analyst Trends and Forecast

2

Jun

1

Aug

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.12B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1506.52

PB Ratio (TTM)

31.69

Earnings Yield % (TTM)

-6.58%

Earnings Yield % (FWD)

-7.08%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.62

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$72.05M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-